Skip to main content

FDA Approvals

Ojjaara FDA Approved for Treatment of Myelofibrosis and Anemia

Exxua, a First-in-Class Oral Selective 5-HT1A Receptor Agonist, FDA Approved for Major Depressive Disorder

FDA Approves Pombiliti Plus Opfolda for Treatment of Pompe Disease

Tofidence, First Biosimilar to Actemra, FDA Approved for Rheumatoid Arthritis and 2 Forms of Juvenile Idiopathic Arthritis

FDA Approved Rivfloza for Treatment of Primary Hyperoxaluria Type 1 in Children and Adults

Braftovi Plus Mektovi Now FDA Approved for Treatment of Metastatic Non–Small Cell Lung Cancer With BRAF Mutation

Opdivo Now Approved for Adjuvant Treatment of Stage IIB/C Melanoma

Keytruda Now Approved for Neoadjuvant and Adjuvant Treatment of Resectable Non–Small Cell Lung Cancer

FDA Approvals, Bispecific Antibodies

FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM

FDA Approved Izervay for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

Page 3 of 21
Results 21 - 30 of 205